Galapagos NV and AbbVie Inc have announced progress in their cystic fibrosis drug collaboration and restated their goal of developing a combination therapy for patients with the most common genetic defect – the Delta F508 mutation. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News Clinical Research
